Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA is investigating the risk of new T-cell malignancies among patients receiving the engineered T cells, but so far, cases are rare.
The Leukemia & Lymphoma Society’s Lee Greenberger rounds up exciting study results from ASH 2023 and emerging themes for the future.
Fred Hutch scientists prevent metastasis by boosting cancer-killing T cells in patients, primarily those with breast cancer.
CAR-T expert Terry Fry of the University of Colorado Cancer Center talks about new data and future applications for this immunotherapy.
Findings show benefits of AI-driven techniques, chemotherapy-free treatments, and cell therapy.
Findings suggest “less is more” and “tried and true” may benefit select patients.
Early research in animals shows potential against cervical cancer and neuroblastoma.
The novel treatment is successful for blood cancers, but results in patients with solid tumors have not been nearly as impressive.
Shivani Srivastava receives NCI MERIT Award to investigate how to improve engineered cancer immunotherapies against solid tumors.
Rosenberg pioneered cancer treatments including tumor-infiltrating lymphocytes and CAR-T therapy.
Novel treatment relies on a newer form of CRISPR gene-editing technology called base editing.
University of Colorado experts discuss the drugs Scemblix and Tecartus and the broader context of leukemia research today.
The Leukemia & Lymphoma Society’s Dare to Dream project helps pediatric cancer patients like Cayden, who received CAR-T therapy.
UCSF Parnassus researchers look to other diseases for new treatments, such as links between diabetes and cancer immunotherapy.
“I envision LLS continuing to be a leading innovator, driving change that impacts all cancer care,” says E. Anders Kolb, MD.
Report includes call to action outlining steps Congress must take to maintain momentum.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.